Co-Diagnostics Shares Are Trading Higher After the Company Announced It Performed an in Silico Analysis of the Co-Dx Logix Smart Mpox RUO Test to Evaluate the Possible Impact of Clade Ib Mpox on the Test. Results Showed That the Test Should Retain...
Co-Diagnostics Shares Are Trading Higher After the Company Announced It Performed an in Silico Analysis of the Co-Dx Logix Smart Mpox RUO Test to Evaluate the Possible Impact of Clade Ib Mpox on the Test. Results Showed That the Test Should Retain...
Co-Diagnostics股價上漲，因爲公司宣佈已對Co-Dx Logix Smart Mpox RUO試驗進行了in silico分析，評估了Clade Ib Mpox對試驗的可能影響。結果顯示該試驗應該保留對過去一年中流行的Mpox毒株的充分反應性，包括Clade 1b。
Co-Diagnostics Shares Are Trading Higher After the Company Announced It Performed an in Silico Analysis of the Co-Dx Logix Smart Mpox RUO Test to Evaluate the Possible Impact of Clade Ib Mpox on the Test. Results Showed That the Test Should Retain Full Reactivity Against Mpox Strains Circulating Over the Last Year, Including Clade 1b.
Co-Diagnostics股價上漲，因爲該公司宣佈對Co-Dx Logix Smart Mpox RUO測試進行了in Silico分析，以評估Clade Ib Mpox可能對測試的影響。結果顯示，該測試應該對過去一年流行的Mpox菌株保持完全反應性，包括Clade 10億。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。